Clinical trial NCT06892093: Probiotics for Prevention of Pyrotinib/Neratinib-Induced Diarrhea in Breast Cancer Patients
Official title: Efficacy and Safety of Probiotics Versus Standard Care in Preventing Diarrhea Induced by Pyrotinib/Neratinib in Breast Cancer Patients: A Prospective Randomized Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: HER2-positive Breast Cancer
Diarrhea Caused by Drug
Neratinib
Pyrotinib
Keywords: Pyrotinib
Neratinib
Probiotics
Diarrhea
Breast Cancer
Lead sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sponsor class: OTHER
Collaborators: name: Jiangnan University
First posted: 2025-03-24
Enrollment: 308
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to evaluate the efficacy and safety of probiotics for the prevention of diarrhea in patients with breast cancer receiving tyrosine kinase inhibitors (TKIs), specifically Pyrotinib or Neratinib.

Study Design: This is a prospective, randomized controlled clinical trial. Participants will be randomly assigned to either a probiotics intervention group or a placebo-controlled group. Both groups will be permitted to use loperamide as needed for diarrhea management.

Primary Objective: To evaluate the efficacy of probiotics in reducing the incidence and severity of diarrhea in patients receiving TKIs.

Secondary Objectives: This study will also investigate the effects of probiotics on gut microbiota composition and their potential impact on drug efficacy.

Study Duration: Patient enrollment is expected to take place from January 2025 to June 2027 at Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University. Both the intervention and control groups will receive treatment for 12 weeks, followed by a 4-week post-intervention observation period, making the total study duration 16 weeks.

Eligibility Criteria: Participants must be diagnosed with HER2-positive breast cancer and scheduled to receive Pyrotinib or Neratinib. Exclusion criteria include patients with severe gastrointestinal disorders or recent probiotic consumption.

Detailed description: Breast cancer patients treated with tyrosine kinase inhibitors (TKIs), such as Pyrotinib and Neratinib, often experience severe diarrhea, leading to treatment interruptions, dose reductions, or discontinuation. Emerging evidence highlights the role of gut microbiota in drug metabolism and gastrointestinal toxicity. Probiotics have been proposed as a potential intervention to modulate gut microbiota and mitigate diarrhea; however, their efficacy in preventing TKI-induced diarrhea remains inconclusive.

This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy and safety of probiotics in preventing diarrhea in HER2-positive breast cancer patients receiving TKIs. The study will also explore the impact of probiotics on gut microbiota composition and potential microbiome-mediated mechanisms that may enhance treatment adherence and therapeutic outcomes.

Metagenomic sequencing and targeted metabolomics will be performed on stool and blood samples to investigate gut microbial composition and metabolic changes. Additional analyses will assess the association between gut-derived metabolites and immune cell activation, aiming to elucidate potential interactions among gut microbiota, metabolites, and immune responses.

Eligibility criteria: Inclusion Criteria:

Participants must meet all of the following criteria:

1. Female patients aged ≥18 years, diagnosed with HER2-positive breast cancer.
2. Eligible for pan-HER TKI therapy, including Pyrotinib or Neratinib, based on clinical guidelines.
3. ECOG performance status ≤ 2, with an expected survival of at least 3 months.
4. Left ventricular ejection fraction (LVEF) ≥ 50%.
5. Resolution of prior treatment-related toxicity to Grade ≤1 (CTCAE v5.0), with AST and ALT ≤ 2.5 times the upper normal limit, and total bilirubin ≤ 1.5 times the upper normal limit.
6. Adequate bone marrow function, defined as white blood cell count ≥ 3.0 × 10⁹/L, neutrophil count ≥ 1.5 × 10⁹/L, platelet count ≥ 100 × 10⁹/L, hemoglobin ≥ 90 g/L, and serum creatinine ≤ 1.5 times the upper normal limit.
7. No persistent gastrointestinal symptoms (e.g., hematochezia, chronic constipation, or abdominal pain).
8. No evidence of structural gastrointestinal abnormalities based on gastroscopy or other relevant examinations.

Exclusion Criteria:

Patients will be excluded if they meet any of the following criteria:

1. Conditions that impair swallowing or drug absorption.
2. Presence of other gastrointestinal diseases, including but not limited to inflammatory bowel disease or gastrointestinal tumors.
3. Severe cardiovascular disease or conditions incompatible with chemotherapy, including but not limited to life-threatening arrhythmias, advanced atrioventricular block, unstable angina, clinically significant pericardial disease, myocardial fibrosis, or uncontrolled hypertension.
4. Known hypersensitivity to any active ingredient or component of the investigational drug.
5. Prior radiotherapy, chemotherapy, endocrine therapy, or investigational drug trials within 4 weeks before enrollment, or history of chronic use of constipation-inducing medications within 6 months before enrollment.
6. Pregnant or lactating women or those unwilling to adopt effective contraception during the study period.
7. Any condition, at the investigator's discretion, that may compromise patient safety, interfere with study participation, or affect the interpretation of study results.

Primary outcomes:
measure: Occurrence of Grade 3 or Higher Diarrhea
timeFrame: Up to 12 weeks
Secondary outcomes:
measure: Occurrence of Grade 2 or Higher Diarrhea
timeFrame: Up to 12 weeks
measure: Duration of Diarrhea
timeFrame: Up to 12 weeks
measure: Hospitalization Rate Due to Diarrhea
timeFrame: Up to 12 weeks
measure: Loperamide Use
timeFrame: Up to 12 weeks
measure: Change from Baseline in Overall Quality of Life Assessed by EORTC QLQ-C30
timeFrame: Baseline, Weeks 2, 4, 8, 12, and 16 (End of Study)
measure: Change from Baseline in Diarrhea-Related Quality of Life Assessed by FACT-D
timeFrame: Baseline, Weeks 2, 4, 8, 12, and 16 (End of Study)
measure: Incidence of Treatment-Related Adverse Events (AEs)
timeFrame: Up to 16 weeks
measure: Incidence of Serious Adverse Events (SAEs)
timeFrame: Up to 16 weeks
measure: Treatment Discontinuation Rate Due to Adverse Events
timeFrame: Up to 16 weeks
Other outcomes:
measure: Gut Microbiota Composition Changes
timeFrame: Baseline and Week 12
measure: Changes in Gut Microbiota-Associated Metabolites
timeFrame: Baseline and Week 12
measure: Changes in Peripheral Blood Immune Cell Proliferation and Differentiation
timeFrame: Baseline and Week 12
measure: Correlation Analysis of Gut Microbiota-Metabolite-Immune Axis
timeFrame: Up to 12 weeks
Locations:
city: Guangzhou
country: China
facility: Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
state: Guangdong
Study officials:
References: